What question did this study set out to answer?

The study aims to determine the prevalence and clinical implications of ESBL and AmpC coproduction in uropathogenic E. coli among diabetic and nondiabetic patients.

February 6, 2026Open Access

Clinical Significance of Extended-Spectrum β-Lactamase (ESBL) and AmpC β-Lactamase (AmpC) Coproduction among Uropathogenic Escherichia coli from Diabetic and Nondiabetic Patients: Implications for Antimicrobial Resistance and Treatment Outcomes

Key Points

The study aims to determine the prevalence and clinical implications of ESBL and AmpC coproduction in uropathogenic E. coli among diabetic and nondiabetic patients.
Conducted a cross-sectional study with 300 adult patients from Misurata Medical Center.
Collected midstream urine specimens and performed antimicrobial susceptibility testing.
Identified ESBL and AmpC coproduction using double-disk synergy and inhibitor-based disk tests.
Analyzed data using SPSS and R, applying statistical tests for comparison and predictors of treatment outcomes.
Total prevalence of ESBL, AmpC, and coproduction was 58.3%, 14.3%, and 14.0%, respectively.
Coproduction was significantly higher in diabetic patients (22%) compared to nondiabetic patients (6%; p < 0.001).
93% of coproducing strains exhibited extensive multidrug resistance.
Diabetes mellitus and prior antibiotic exposure were significant predictors of coproduction.

Abstract

Urinary tract infections (UTIs) caused by Escherichia coli remain a major global health burden, particularly among diabetic patients who are prone to recurrent and complicated infections. This article determines the prevalence, antimicrobial resistance patterns, and clinical predictors of extended-spectrum β-lactamase (ESBL) and AmpC β-lactamase coproduction among uropathogenic E. coli isolates. Cross-sectional study was conducted on 300 adult patients with culture-confirmed E. coli UTIs at Misurata Medical Center, including 150 people living with diabetes (PLWD) and 150 nondiabetic participants. Midstream urine specimens were collected and cultured on standard media. Antimicrobial susceptibility testing followed the Clinical and Laboratory Standards Institute 2024 guidelines, while ESBL and AmpC β-lactamases were phenotypically detected using the double-disk synergy and inhibitor-based disk tests. Data were analyzed using SPSS v27 and R v4.3.2. Categorical and continuous variables were compared using chi-square/Fisher's exact and Mann–Whitney U tests, respectively. Predictors of coproduction and its impact on treatment failure were identified via multivariate logistic regression; a p-value of < 0.05 was considered statistically significant. The total prevalence of ESBL, AmpC, and ESBL + AmpC coproduction was 58.3, 14.3, and 14.0%, respectively. While the prevalence of ESBL-only and AmpC-only phenotypes did not differ significantly between PLWD and nondiabetic patients, coproduction was significantly higher in PLWD (22%) compared with nondiabetic patients (6%; p < 0.001) and was associated with extensive multidrug resistance (93%). Diabetes mellitus (adjusted odds ratio OR = 3.64; p = 0.001) and prior antibiotic exposure (adjusted OR = 2.18; p = 0.041) were independent predictors of coproduction. ESBL + AmpC coproduction in uropathogenic E. coli represents an emerging therapeutic and epidemiological concern, particularly among PLWD. Routine AmpC screening and rational antibiotic policies are urgently required to mitigate treatment failure and limit resistance.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper